Executives On The Move: Defectors From GSK, Pfizer, Shire, Dr Reddy's Get New Posts
Oxstem, ProMIS Neurosciences, resTORbio and Ultragenyx Pharmaceuticals are among firms recently announcing senior executive hires from the management ranks of big pharma. Meanwhile, Boehringer Ingelheim, Kane Biotech and Relypsa have all reported fresh resignations.
You may also be interested in...
Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.
Having kept out of the race to develop a vaccine until now, Novartis has joined efforts with a collaboration using the AAV gene therapy vector.
Multiple vaccine and drug developers across the world report progress and partnerships amid volatility in their shares.